At this point, who cares? This message board has been asking why it was not updated years ago. Who here thinks the majority of the most influential shareholders view the clinical trial sites?
If you do not have the attention of Wall Street movers you are losing. You need exposure to Wall Street and good investors stay away when management has been shown to burn them over and over and over again. The reason Fife looks at us as his dinner.
I'm now looking forward to the ASCO talk and a journal article and the Company's TLD, as they can now all refer to the Clinical Trials website's primary and secondary endpoints. And we know how good those are.